This is a working overview of MC4 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-16 and is reviewed periodically as new material appears.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Stability depends heavily on physical state. Lyophilized powder held dry, cold and dark retains its content over long periods, whereas dissolved peptide begins to change within days at room temperature. The most cited degradation route is oxidation of the methionine residue, which converts the peptide to a sulfoxide form that elutes differently on chromatography. Hydrolysis of amide bonds and adsorption onto container walls contribute smaller losses. Buffers that exclude oxygen from the headspace slow the oxidation pathway, but no single condition prevents all change indefinitely.
Practical handling follows from those properties. Bulk material is best divided into single-use portions soon after receipt, because each thaw exposes the whole container to moisture and temperature cycling. Vials should be allowed to reach room temperature before opening to prevent condensation on the powder. Low-binding plasticware reduces loss of dilute solutions, and sterile filtration is used when a preparation must remain free of microbial growth. Records of batch number, reconstitution date and storage history are what allow a later analytical result to be interpreted meaningfully.
Identity and purity of Semax are established mainly by reversed-phase high-performance liquid chromatography coupled with mass spectrometry. The chromatographic trace gives a purity estimate as a percentage of total peak area, while electrospray or matrix-assisted laser desorption ionization confirms the molecular mass against the calculated value. Amino acid analysis and sequence-specific fragmentation provide further confirmation when a supplier's chain of custody is unclear. Vendors frequently quote a purity figure without stating the detection wavelength or the integration method, which limits how far one number can be compared with another.
Corneal cross-linking involves application of riboflavin solution to the eye that is activated by illumination with UV-A light for approximately 30 or fewer minutes. The riboflavin causes new bonds to form across adjacent collagen strands and proteoglycans in the stromal layer of the cornea, which recovers and preserves some of the cornea's mechanical strength. The corneal epithelial layer is generally removed to increase penetration of the riboflavin into the stroma, a procedure known as the Dresden protocol. People that are considered for treatment must undergo an extensive clinical workup, including corneal tomography, computerized corneal topography, endothelial microscopy, ultrasound pachymetry, b-scan sonography, keratometry and biomicroscopy.
For example, the dioxide (FlO2) is expected to be highly unstable to decomposition into its constituent elements (and would not be formed by direct reaction of flerovium with oxygen), and flerovane (FlH4), which should have Fl–H bond lengths of 1.787 Å and would be the heaviest homologue of methane (the lighter compounds include silane, germane and stannane), is predicted to be more thermodynamically unstable than plumbane, spontaneously decomposing to flerovium(II) hydride (FlH2) and H2. The tetrafluoride FlF4 would have bonding mostly due to sd hybridizations rather than sp3 hybridizations, and its decomposition to the difluoride and fluorine gas would be exothermic. The other tetrahalides (for example, FlCl4 is destabilized by about 400 kJ/mol) decompose similarly. The corresponding polyfluoride anion FlF2−6 should be unstable to hydrolysis in aqueous solution, and flerovium(II) polyhalide anions such as FlBr−3 and FlI−3 are predicted to form preferentially in solutions. The sd hybridizations were suggested in early calculations, as flerovium's 7s and 6d electrons share about the same energy, which would allow a volatile hexafluoride to form, but later calculations do not confirm this possibility. In general, spin–orbit contraction of the 7p1/2 orbital should lead to smaller bond lengths and larger bond angles: this has been theoretically confirmed in FlH2. Still, even FlH2 should be relativistically destabilized by 2.6 eV to below Fl+H2; the large spin–orbit effects also break down the usual singlet–triplet divide in the group 14 dihydrides.
=== Formulation === The health benefits of a alpha-glucosidase-inhibiting herb powder were shown to be stronger when the powder is consumed orally dissolved in water as a beverage in comparison to its intake as ordinary hard gelatin capsules. The package insert of acarbose tablet lists two ways to take it: chewing it down with the first bites of food, or swallowing it some time before eating. With the same brand of acarbose tablet, chewing food appears effective than swallowing in combating the blood sugar rise from drinking sucrose water.
Sources: en.wikipedia.org
=== The theory of protein crystallization === Protein crystallization is governed by the same physics that governs the formation of inorganic crystals. For crystallization to occur spontaneously, the crystal state must be favored thermodynamically. This is described by the Gibbs free energy (∆G), defined as ∆G = ∆H- T∆S, which captures how the enthalpy change of a process, ∆H, trades off with the corresponding change in entropy, ∆S. Entropy, roughly, describes the disorder of a system. Highly ordered states, such as protein crystals, are disfavored thermodynamically compared to more disordered states, such as solutions of proteins in solvent, because the transition to a more ordered state would decrease the total entropy of the system (negative ∆S). For crystals to form spontaneously, the ∆G of crystal formation must be negative. In other words, the entropic penalty must be paid by a corresponding decrease in the total energy of the system (∆H). Familiar inorganic crystals such as sodium chloride spontaneously form at ambient conditions because the crystal state decreases the total energy of the system. However, crystallization of some proteins under ambient conditions would both decrease the entropy (negative ∆S) and increase the total energy (positive ∆H) of the system, and thus does not occur spontaneously. To achieve crystallization of such proteins conditions are modified to make crystal formation energetically favorable. This is often accomplished by creation of a supersaturated solution of the sample.
This gives the antivenin its polyvalent property. This also enhances the potency of the antivenin. Some venoms cannot induce the immune system enough on its own or the combination of two or more venoms result in a better responding antivenin.
=== 20 April === Two people were killed in a Russian attack on Vovchansk. One person was killed in a separate attack in Dnipropetrovsk Oblast. Ukrainian forces claimed responsibility for strikes on Russian energy infrastructure, with fires breaking out in three electrical substations in Smolensk, Kaluga and Bryansk Oblasts. A fuel storage tank belonging to Lukoil was set on fire in Smolensk Oblast by falling drone debris. The Russian ministry of defence claimed to have shot down some fifty drones over the said oblasts as well as in Ryazan, Tula, Moscow, Kursk and Belgorod Oblasts, where two people were claimed to have died. The US House of Representatives passed a $61 billion aid package for Ukraine. It must be passed by the Senate and signed into law by President Joe Biden.
== History == Scientists in Japan began to collaborate as early as 1939 on the development of an electron microscope. Kenji Kazato and Kazuo Ito met while working at the Naval Central Institute in Tokyo during World War II. After the war, Kazato attracted Ito and a group of others to Mobara, Chiba Prefecture, Japan. This initial group developed a prototype magnetic field–type electron microscope called the DA-1, which was sold to Mitsubishi in 1947. Because of differences over the direction of this early company, Kazato and Ito chose to found a new organization. The Japan Electron Optics Laboratory Company, Limited (Nihon Denshi Kogaku Kenkyujo) was founded in 1949 by Kenji Kazato and Kazuo Ito in Mitaka, Tokyo. It produced its first commercial model transmission electron microscope, the JEM-1, a year later. Overseas sales began in 1956 with the sale of a system to France. The company's strengths were the customization of orders to fit customer requests, and the provision of strong customer support. In 1961, the company was renamed JEOL, Limited. Its first overseas subsidiary, JEOL Company (USA) Inc., was established in 1962 and headquartered in Peabody, MA. JEOL was listed on the Second Section of the Tokyo Stock Exchange by 1962, and on the First Section of the Tokyo Stock Exchange by 1966. The company expanded from electron microscopy to nuclear magnetic resonance (NMR), releasing the first NMR system in Japan, the JNM-1, in 1956. They produced their first mass spectrometer in 1963, and their first scanning electron microscope in 1966.
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.